CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 86 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q3 2017. The put-call ratio across all filers is 1.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $35,749,000 | -77.8% | 302,675 | -79.2% | 3.52% | -60.9% |
| Q3 2020 | $161,361,000 | +17.2% | 1,451,870 | +7.7% | 9.00% | -1.0% |
| Q2 2020 | $137,728,000 | +49.9% | 1,347,897 | +58.3% | 9.09% | +66.2% |
| Q1 2020 | $91,899,000 | -28.4% | 851,474 | -22.7% | 5.47% | -26.1% |
| Q4 2019 | $128,270,000 | +6.6% | 1,102,163 | +4.8% | 7.40% | +32.6% |
| Q3 2019 | $120,358,000 | +11.9% | 1,051,438 | -6.8% | 5.58% | +27.9% |
| Q2 2019 | $107,567,000 | +18.9% | 1,128,717 | +13.9% | 4.36% | +7.7% |
| Q1 2019 | $90,450,000 | -1.4% | 991,233 | -17.9% | 4.05% | -27.3% |
| Q4 2018 | $91,690,000 | -1.8% | 1,207,869 | +3.4% | 5.57% | +88.6% |
| Q3 2018 | $93,411,000 | +13.6% | 1,167,643 | +41.1% | 2.95% | +47.5% |
| Q2 2018 | $82,219,000 | +197.1% | 827,738 | +142.3% | 2.00% | +221.9% |
| Q1 2018 | $27,671,000 | +118.4% | 341,616 | +112.4% | 0.62% | +102.6% |
| Q4 2017 | $12,670,000 | +353.1% | 160,847 | +430.9% | 0.31% | +403.3% |
| Q3 2017 | $2,796,000 | – | 30,298 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Maso Capital Partners Ltd | 164,500 | $15,011,000 | 10.32% |
| HHLR ADVISORS, LTD. | 2,751,200 | $251,047,000 | 6.99% |
| Dalton Investments, Inc. | 113,851 | $10,389,000 | 4.54% |
| Point72 Hong Kong Ltd | 115,939 | $10,579,000 | 4.17% |
| York Capital Management Global Advisors, LLC | 991,233 | $90,450,000 | 4.05% |
| RUDMAN ERROL M | 58,000 | $5,293,000 | 3.57% |
| Greenwoods Asset Management Ltd | 479,580 | $43,762,000 | 2.69% |
| Parametrica Management Ltd | 3,663 | $334,000 | 0.71% |
| Temasek Holdings (Private) Ltd | 990,000 | $90,338,000 | 0.62% |
| Athos Capital Ltd | 8,290 | $756,000 | 0.49% |